Omicia

We help researchers and clinicians understand, interpret, and report on DNA sequencing data

Opal™, Omicia’s comprehensive genome interpretation platform, significantly improves the accuracy, speed, and cost of translating DNA sequencing data into actionable information.

Opal is designed for:

  • Disease research
  • Diagnostic testing and reporting
  • Clinical trials management and drug development

Schedule a free demo and learn how Opal can work for you

A primer on genome interpretation:
How Omicia is transforming personalized medicine


Opal Genome Interpretation Platform

Next-generation genome interpretation and reporting software

  • Annotate genomes and exomes
  • Identify disease-causing gene variants
Learn more about Opal Research >>
  • Develop NGS disease gene panels & diagnostic tests
  • Generate customizable clinical reports
Learn More about Opal Clinical >>
  • Identify genomic biomarkers
  • Design more intelligent clinical trials
Learn more about Opal Clinical Trials >>

Our Customers

Omicia continues to lead the genome analysis field by partnering with world-renowned institutions. Their invaluable contributions and feedback keep Omicia at the forefront of clinical genome interpretation.

aruplabs
cornell
ecolepoly
uofvienna
uofutah
uofmiami
ucsc
osaka
mahidol
mountsinai
kiel
johnhopkins
ucsf
craig-venter
ngi
coldspring

Recent News


June 25, 2014
Omicia taps renowned clinical and genomics experts for scientific advisory board

Read More

June 3, 2014
Omicia and LabCorp collaborate to offer comprehensive genomic analysis services for next-generation clinical trials

Read more

March 18, 2014
Omicia co-founder & president, Martin Reese, speaks to Mendelspod about scaling up clinical interpretation of the human genome

Watch the interview